FSP Answered: How New Partnership Models are Shaping Client-Provider Relationships

Traditionally, biopharmaceutical companies have conducted many business-critical functions in-house, but, as drug development costs and labor demands continue to increase, companies need more efficient and cost-effective approaches to manage their workload without sacrificing the high-quality results needed to meet Food and Drug Administration (FDA) guidelines and bring new drugs to market.

To help address these needs, PPD offers a variety of functional service provider (FSP) models, ranging from simple insourcing staffing models to more complex, multifunctional agreements. Each model is designed to meet the specific needs of the service offering and needs of the client. Through the industry expertise and knowledge gained from our 27-plus year history as a global CRO, PPD uses FSP as one of several constructs to meet our clients’ need for more flexible outsourcing models.

PPD takes the FSP model to a new level, identifying and implementing broad, portfolio-based functions in configurations that streamline operations, enhance quality improvement, and advance the client-provider relationship towards true partnership.

Key Takeaways

• Gain answers, insights and solutions to the evolving world of FSP
• Understand the need for new service models and PPD’s novel approach to the FSP partnership
• Learn how an FSP relationship can streamline operations, improve quality and advance client-provider relationships
• Discover the flexibility and efficiencies offered through an FSP partnership

Speaker

Bryan Haas, Pharm.D., Vice President, Functional Service Partnerships, PPD

Bryan Haas, Pharm.D., is vice president of functional services partnerships (FSP). In this role, he directly oversees the global FSP business unit and its strategic direction. He also maintains client relationships through the joint executive oversight committee; provides overall strategy, direction, and oversight to FSP functions; and disseminates best practices within operating groups.

Bryan joined PPD in 1999 as a clinical research associate, assuming roles of increasing responsibility, leading to his promotion to executive director of global operations analytics in 2009, executive director of North American clinical management in 2010 and his current position in 2012. In addition to his clinical management experience, Bryan is a licensed pharmacist with experience in retail and hospital settings. His therapeutic expertise spans the areas of infectious/parasitic diseases, oncology/hematology, endocrine/metabolic, mental disorders, circulatory and respiratory.

Bryan earned a doctor of pharmacy, a master of science in hospital pharmacy administration and a bachelor of science in pharmacy from the University of North Carolina at Chapel Hill, where he also completed a pharmacy practice residency. He is a member of the American Society of Clinical Oncology.

Message Presenter